Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q3 EPS of $0.10, $0.08 better than the analyst estimate of $0.02. Revenue for the quarter came in at $67.77 million versus the consensus estimate of $57.48 million.

GUIDANCE:

Aurinia Pharmaceuticals sees FY2024 revenue of $210-220 million, versus the consensus of $234.2 million.

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.